All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IN-001
Therapeutic Area: Immunology Product Name: IN-001
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: HLK Pharmacin
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 29, 2020
Details:
The Phase 1 single dose study in healthy volunteers will compare IN-001 orally dissolving tablet (epinephrine prodrug) vs the current standard of care, EPIPEN (epinephrine injection).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): INT301
Therapeutic Area: Immunology Product Name: INT301
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: Intrommune Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 20, 2020
Details:
Based on this deal, Circuit Clinical will oversee the early clinical development of Intrommune’s lead drug, INT301, including a Phase 1b study planned for Q4 2020 and Q1 2021.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Lentivirus-Hematopoietic Stem Cell
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: IND Enabling Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2020
Details:
Expression Therapeutics has developed a promising and potentially curative gene therapy candidate for familial hemophagocytic lymphohistiocytosis (HLH) type 3 (FHL3).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tivozanib
Therapeutic Area: Immunology Product Name: Fotivda
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Kyowa Kirin
Deal Size: $433.5 million Upfront Cash: $25.0 million
Deal Type: Agreement August 05, 2020
Details:
The milestone relates to acceptance by the Japanese Pharmaceuticals and Medical Devices Agency of an investigational new drug (IND) application for tivozanib in a non-oncology indication being developed by Kyowa Kirin.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: BRYN-NDS1C
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $26.0 million Upfront Cash: Undisclosed
Deal Type: Financing August 04, 2020
Details:
Proceeds from the financing will be used to fund the remaining development and regulatory approval activities, and pre-launch commercialization program for BRYN-NDS1C, Bryn's bi-dose epinephrine nasal spray.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): FCR001
Therapeutic Area: Immunology Product Name: FCR001
Highest Development Status: IND Enabling Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 08, 2020
Details:
Approval of this IND allows Talaris to initiate a Phase 1/2a trial for the evaluation of Talaris’ novel cell therapy FCR001 in the treatment of diffuse systemic sclerosis, at sites across the U.S., including Duke University and the University of Michigan.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): GP1681
Therapeutic Area: Immunology Product Name: GP1681
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Richard King Mellon Foundation
Deal Size: $0.2 million Upfront Cash: Undisclosed
Deal Type: Funding July 07, 2020
Details:
The funding would accelerate the development of CytoAgents' lead drug candidate, GP1681, an investigational new drug to treat “cytokine storm” induced by COVID-19, from the Richard King Mellon Foundation.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CD45-ADC
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2020
Details:
Single dose of CD45-ADC shown to remove disease-causing cells and halt disease in models of multiple sclerosis, systemic sclerosis and inflammatory arthritis.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Desmoglein 3 Chimeric AutoAntibody Receptor T cells
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: IND Enabling Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 06, 2020
Details:
U.S. FDA has granted Fast Track Designation for DSG3-CAART, the Cabaletta’s lead product for treatment of mucosal pemphigus vulgaris, for improving healing of mucosal blisters in patients with mPV.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
